Gritstone Bio Inc
GRTS
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.8M
Close$
$-0.62
2022.4% downside
Current Fair Value
2022.4% downsideOvervalued by 2022.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.80 Million |
|---|---|
| Enterprise Value | $-7,890.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.2 |
| Beta | 0.5 |
| Outstanding Shares | 143,296,662 |
Return
| Return on Equity | -599.54% |
|---|---|
| Return on Assets | -93.33% |
| Return on Invested Capital | -127.56% |
Valuation & Multiples
| P/E Ratio | -0.03 |
|---|---|
| PEG | 0.08 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -6129.66 |
| Debt to Equity | 2.18 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Gritstone Oncology Inc
CEO: Andrew Allen